Singapore’s co-developed vaccine candidate is in ‘good shape’ for delivery in 2021


A Covid-19 vaccine candidate co-developed by Singapore scientists has shown positive interim results and could be available as early as 2021.

That’s according to American biopharmaceutical firm Arcturus Therapeutics, which is working with scientists from Duke-NUS Medical School in Singapore, to develop the vaccine.

Early this month, Arcturus announced positive interim clinical study results from its ongoing Phase 1/2 study of its vaccine candidate, ARCT-021.

“One of the unique advantages of the Arcturus vaccine is that it’s a low-dose vaccine, projected to be 7.5 micrograms, which is a much smaller dose than other vaccine prospects currently being evaluated,” Joseph Payne, President and CEO of Arcturus Therapeutics, told CNBC in an interview two weeks ago.

He highlighted that this could possibly yield more doses in each manufacturing run, that will in turn save time and money.

The vaccine is on track to be shipped in early 2021, Arcturus said in a press release. US SPREAD GOOD NEWS!

I run this site in my spare time and thoroughly enjoy giving you all positive news!  If you’ve enjoyed the site we’d love for you to help me share the good news far and wide, share us on Reddit, your Facebook or your Twitter and spread a little positivity around.


Our new page here is just what you need, with just good news, feel good stories unrelated to COVID.

By Justgivemepositivenews Team